TriSalus Life Sciences, Inc.

Surgical & Medical Instruments & Apparatus

TLSI Medical Devices & Diagnostics People in Medical Devices & Diagnostics SEC CIK 0001826667 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$287.25M
61,574,600 shares Covers all 2 share classes this company has on file.
Insiders on file
8
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$33.95M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
11.82%
insider-held value divided by market capitalisation

What TriSalus Life Sciences, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$45.15M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$39.23M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
102
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at TriSalus Life Sciences, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against TriSalus Life Sciences, Inc..
Insider Reported role Shares Value Last action
Officers 1
David Patience CFO 268,657 $1.34M F Shares withheld for taxes Jul 1, 2026 position reported
Officers who also sit on the board 2
Mary T Szela CEO 752,987 $3.76M A Grant or award Jun 30, 2026 position reported
Sean Murphy Other Executive 679,256 $3.40M A Grant or award May 19, 2025 position reported
Directors 5
Mats Wahlstrom Board Member 2,665,202 $13.33M P Open-market purchase May 15, 2026 position reported
Michael P Stansky Board Member 986,830 $4.93M P Open-market purchase May 15, 2026 position reported
David J. Matlin Board Member 941,944 $4.71M A Grant or award May 14, 2026 position reported
George Kelly Martin Board Member 247,176 $1.24M S Open-market sale Aug 28, 2024 position reported
Arjun JJ Desai Board Member 247,127 $1.24M S Open-market sale Dec 10, 2024 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

4 insiders bought TriSalus Life Sciences, Inc. (TLSI) shares worth $1,796,829 on May 15, 2026

Cluster buying

4 different insiders made 5 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.

4 insiders bought TriSalus Life Sciences, Inc. (TLSI) shares worth $1,796,829 on May 15, 2026
Date Insider Transaction Shares Price Value Filing
May 15, 2026 David Patience P Open-market purchase 7,100 held after: 275,757 $2.43 $17,253 SEC filing ↗
May 15, 2026 Mary T Szela P Open-market purchase 39,682 held after: 1,065,215 $2.59 $102,776 SEC filing ↗
May 15, 2026 Michael P Stansky P Open-market purchase 410,000 held after: 1,240,722 $2.50 $1,025,000 SEC filing ↗
May 15, 2026 Michael P Stansky P Open-market purchase 200,000 held after: 399,698 $2.50 $500,000 SEC filing ↗
May 15, 2026 Mats Wahlstrom P Open-market purchase 60,000 held after: 147,555 $2.53 $151,800 SEC filing ↗

Total of the rows above: $1,796,829, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

3 insiders bought TriSalus Life Sciences, Inc. (TLSI) shares worth $1,620,492 on Feb 23, 2026

Cluster buying

3 different insiders made 4 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.

3 insiders bought TriSalus Life Sciences, Inc. (TLSI) shares worth $1,620,492 on Feb 23, 2026
Date Insider Transaction Shares Price Value Filing
Feb 23, 2026 Mary T Szela P Open-market purchase 30,487 held after: 773,289 $4.10 $124,997 SEC filing ↗
Feb 23, 2026 Michael P Stansky P Open-market purchase 243,900 held after: 787,132 $4.10 $999,990 SEC filing ↗
Feb 23, 2026 Michael P Stansky P Open-market purchase 117,198 held after: 199,698 $4.10 $480,512 SEC filing ↗
Feb 23, 2026 David Patience P Open-market purchase 3,657 held after: 268,657 $4.10 $14,994 SEC filing ↗

Total of the rows above: $1,620,492, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 51 rows we hold, 22 are open-market purchases (P) and 4 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for TriSalus Life Sciences, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Jul 1, 2026 David Patience F Shares withheld for taxes 14,650 $4.46 $65.3K SEC filing ↗
Jun 30, 2026 Mary T Szela A Grant or award 3,990 $3.87 $15.4K SEC filing ↗
May 15, 2026 Mats Wahlstrom P Open-market purchase 60,000 $2.53 $151.8K SEC filing ↗
May 15, 2026 Michael P Stansky P Open-market purchase 200,000 $2.50 $500.0K SEC filing ↗
May 15, 2026 Michael P Stansky P Open-market purchase 410,000 $2.50 $1.03M SEC filing ↗
May 15, 2026 Mary T Szela P Open-market purchase 39,682 $2.59 $102.8K SEC filing ↗
May 15, 2026 David Patience P Open-market purchase 7,100 $2.43 $17.3K SEC filing ↗
May 14, 2026 Mats Wahlstrom A Grant or award 34,226 $0.00 $0 SEC filing ↗
May 14, 2026 Mats Wahlstrom A Grant or award 37,602 $0.00 $0 SEC filing ↗
May 14, 2026 David J. Matlin A Grant or award 23,065 $0.00 $0 SEC filing ↗
May 14, 2026 David J. Matlin A Grant or award 28,201 $0.00 $0 SEC filing ↗
May 14, 2026 Michael P Stansky A Grant or award 20,089 $0.00 $0 SEC filing ↗
May 14, 2026 Michael P Stansky A Grant or award 23,501 $0.00 $0 SEC filing ↗
Mar 17, 2026 Mary T Szela S Open-market sale 15,944 $3.85 $61.4K SEC filing ↗
Mar 11, 2026 Mary T Szela S Open-market sale 4,358 $4.13 $18.0K SEC filing ↗
Feb 23, 2026 David Patience P Open-market purchase 3,657 $4.10 $15.0K SEC filing ↗
Feb 23, 2026 Michael P Stansky P Open-market purchase 117,198 $4.10 $480.5K SEC filing ↗
Feb 23, 2026 Michael P Stansky P Open-market purchase 243,900 $4.10 $1,000.0K SEC filing ↗
Feb 23, 2026 Mary T Szela P Open-market purchase 30,487 $4.10 $125.0K SEC filing ↗
Dec 31, 2025 Mary T Szela A Grant or award 2,100 $4.38 $9.2K SEC filing ↗
Nov 24, 2025 David Patience A Grant or award 65,000 $0.00 $0 SEC filing ↗
Nov 24, 2025 Mary T Szela A Grant or award 125,000 $0.00 $0 SEC filing ↗
Nov 24, 2025 Mary T Szela A Grant or award 300,000 $0.00 $0 SEC filing ↗
Aug 14, 2025 David Patience A Grant or award 200,000 $0.00 $0 SEC filing ↗
Jul 31, 2025 David J. Matlin C Conversion of derivative 330,000 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 1 filer holds a position

Who owns TriSalus Life Sciences, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Filers holding a position in TriSalus Life Sciences, Inc.

Funds, trusts and companies that disclose an ownership position in TriSalus Life Sciences, Inc..
Owner Reported role Shares Filed
Frankenius Equity AB TenPercentOwner 6,230,748

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from TriSalus Life Sciences, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from TriSalus Life Sciences, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.